Overview

Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
For patients who meet the inclusion criteria and who agree to participate in this study, the investigators sampled peripheral blood 10cc and performed the analysis for immunologic profile just before the conversion of immune suppressant. At 1 month, 6 month, and 1 year from the conversion of Immune suppressant (CNI to rapamune), the investigators performed tha analysis fo immune profile again. During the study period, the interval of the visit of subclinic and the kinds of laboratory test (Blood and urine test) would not change compared to before the start of this study.
Phase:
N/A
Details
Lead Sponsor:
Seoul St. Mary's Hospital
Treatments:
Calcineurin Inhibitors
Everolimus
Sirolimus